AELMHU is a non-profit association, established in 2011 by a group of pharmaceutical and biotechnology companies, with a strong commitment to research, develop and commercialise innovative therapies to improve the quality of life of patients suffering from rare and ultra-rare diseases.
To contribute to improve the situation of people and families affected by rare or infrequent diseases, promoting the knowledge of their pathologies and the recognition of the therapeutic and social value of orphan drugs.
WE COLLABORATE WITH ORGANISATIONS
patients, public administrations and other stakeholders, with the aim of contributing our knowledge and experience in the treatment of rare diseases.
WE TRAIN AND INFORM
on the value of orphan and ultra-orphan drugs for the treatment of these pathologies.
WE GIVE VISIBILITY
to the special characteristics of rare and ultra-rare diseases
Bodies of GOVERNMENT
The supreme governing body of AELMHU is the General Assembly. This body is composed of all members in their own right and on an equal footing.
The association also has a Board of Directors, which is responsible for managing and representing the association.
The current members of the Board of Directors are:
Mª JOSÉ SÁNCHEZ
JOSÉ LUIS MORENO
Secretary and member
Treasurer and member
The AELMHU technical team supporting the Board of Directors is led by:
AELMHU is made up of small and medium-sized pharmaceutical and biotechnology companies. The common denominator of all of them is their strong commitment to research into rare diseases and the search for innovative therapies to improve the quality of life of patients suffering from these pathologies.
Become a partner
Do you want to join AELMHU?